vs
Side-by-side financial comparison of LENZ Therapeutics, Inc. (LENZ) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $12.5M, roughly 1.1× LENZ Therapeutics, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -133.6%, a 120.4% gap on every dollar of revenue.
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
LENZ vs LSF — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $13.3M |
| Net Profit | $-16.7M | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | -151.1% | -13.5% |
| Net Margin | -133.6% | -13.2% |
| Revenue YoY | — | 15.0% |
| Net Profit YoY | -63.5% | -341.4% |
| EPS (diluted) | $-0.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | $12.5M | $12.9M | ||
| Q2 25 | $5.0M | $12.0M | ||
| Q1 25 | — | $11.7M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | $0 | $11.8M | ||
| Q2 24 | $0 | $10.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-16.7M | $-975.1K | ||
| Q2 25 | $-14.9M | $-362.2K | ||
| Q1 25 | — | $-156.2K | ||
| Q4 24 | — | $-398.4K | ||
| Q3 24 | $-10.2M | $-166.1K | ||
| Q2 24 | $-10.3M | $-239.1K | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | — | -13.5% | ||
| Q3 25 | -151.1% | -7.7% | ||
| Q2 25 | -337.1% | -3.3% | ||
| Q1 25 | — | -1.9% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | — | -2.3% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | — | -11.0% |
| Q4 25 | — | -13.2% | ||
| Q3 25 | -133.6% | -7.6% | ||
| Q2 25 | -298.2% | -3.0% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | -1.4% | ||
| Q2 24 | — | -2.4% | ||
| Q1 24 | — | -10.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.59 | — | ||
| Q2 25 | $-0.53 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.40 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.4M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.9M | $11.5M |
| Total Assets | $210.7M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | $25.4M | $5.1M | ||
| Q2 25 | $37.6M | $3.9M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | $41.0M | $7.9M | ||
| Q2 24 | $84.0M | $7.6M | ||
| Q1 24 | — | $7.1M |
| Q4 25 | — | $11.5M | ||
| Q3 25 | $193.9M | $12.8M | ||
| Q2 25 | $206.4M | $13.4M | ||
| Q1 25 | — | $13.3M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $215.3M | $13.1M | ||
| Q2 24 | $192.9M | $12.6M | ||
| Q1 24 | — | $12.7M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | $210.7M | $18.9M | ||
| Q2 25 | $217.3M | $20.4M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | $224.0M | $18.8M | ||
| Q2 24 | $202.6M | $18.0M | ||
| Q1 24 | — | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $68.4K |
| Free Cash FlowOCF − Capex | $-9.0M | — |
| FCF MarginFCF / Revenue | -72.2% | — |
| Capex IntensityCapex / Revenue | 3.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-47.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $68.4K | ||
| Q3 25 | $-8.6M | $1.2M | ||
| Q2 25 | $-11.5M | $-2.8M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $339.2K | ||
| Q3 24 | $-10.6M | $305.8K | ||
| Q2 24 | $-15.8M | $642.7K | ||
| Q1 24 | — | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | $-9.0M | — | ||
| Q2 25 | $-11.7M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-10.8M | — | ||
| Q2 24 | $-15.9M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -72.2% | — | ||
| Q2 25 | -235.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LENZ
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
